Samarium-153 EDTMP has recently been introduced, which localizes by a mechanism similar to that for strontium-89, i.e. substitution for calcium in the bone matrix. Toilet practices as for iodine-131 ...

Pluvicto™ (formerly 177Lu-PSMA-617) is a radioligand therapy that was approved by the FDA in March 2022 to treat progressive, PSMA positive metastatic castration-resistant prostate cancer. Pluvicto™ ...